MedElevator Войти в исследования
← Поиск публикаций

DOI 10.7326/0003-4819-137-2-200207160-00008

Медицинская библиотека · Annals of internal medicine · 2002

Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS.

Johnson Philip C, Wheat L Joseph, Cloud Gretchen A, Goldman Mitchell, Lancaster Dan, Bamberger David M, Powderly William G, Hafner Richard, Kauffman Carol A, Dismukes William E, U.S. National Institute of Allergy and Infectious Diseases Mycoses Study Group

Клиническое исследованиеСравнительное исследованиеСтатьяМногоцентровое исследованиеРандомизированное исследованиеПоддержка исследования: вне правительства СШАПоддержка службы здравоохранения СШАПеревод пока не подготовлен

Аннотация

BACKGROUND

In patients with moderate to severe histoplasmosis associated with AIDS, the preferred treatment has been the deoxycholate formulation of amphotericin B. However, serious side effects are associated with use of amphotericin B.

OBJECTIVE

To compare amphotericin B with liposomal amphotericin B for induction therapy of moderate to severe disseminated histoplasmosis in patients with AIDS.

DESIGN

Randomized, double-blind, multicenter clinical trial.

SETTING

21 sites of the U.S. National Institute of Allergy and Infectious Diseases Mycoses Study Group.

PATIENTS: 81 patients with AIDS and moderate to severe disseminated histoplasmosis.

MEASUREMENTS: Clinical success, conversion of baseline blood cultures to negative, and acute toxicities that necessitated discontinuation of treatment.

RESULTS

Clinical success was achieved in 14 of 22 patients (64%) treated with amphotericin B compared with 45 of 51 patients (88%) receiving liposomal amphotericin B (difference, 24 percentage points [95% CI, 1 to 52 percentage points]). Culture conversion rates were similar. Three patients treated with amphotericin B and one treated with liposomal amphotericin B died during induction (P = 0.04). Infusion-related side effects were greater with amphotericin B (63%) than with liposomal amphotericin B (25%) (P = 0.002). Nephrotoxicity occurred in 37% of patients treated with amphotericin B and 9% of patients treated with liposomal amphotericin B (P = 0.003).

CONCLUSION

Liposomal amphotericin B seems to be a less toxic alternative to amphotericin B and is associated with improved survival.

Для цитирования: Johnson Philip C, Wheat L Joseph, Cloud Gretchen A, Goldman Mitchell, Lancaster Dan, Bamberger David M, Powderly William G, Hafner Richard, Kauffman Carol A, Dismukes William E, U.S. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS.. Annals of internal medicine. 2002. DOI: 10.7326/0003-4819-137-2-200207160-00008.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.